about
Self-renewal of acute lymphocytic leukemia cells is limited by the Hedgehog pathway inhibitors cyclopamine and IPI-926Hyperbaric oxygen improves engraftment of ex-vivo expanded and gene transduced human CD34⁺ cells in a murine model of umbilical cord blood transplantation.Pulmonary manifestations of the pre-engraftment syndrome after umbilical cord blood transplantation.Tubacin suppresses proliferation and induces apoptosis of acute lymphoblastic leukemia cells.IgG kappa monoclonal gammopathy of undetermined significance presenting as acquired type III Von Willebrand syndrome.Prognostically important molecular markers in cytogenetically normal acute myeloid leukemia.Skin Recurrence of Transformed Mycosis Fungoides Postumbilical Cord Blood Transplant despite Complete Donor Chimerism.Intestinal ischemia after allogeneic stem cell transplantation: a report of four cases.Rates of complete diagnostic testing for patients with acute myeloid leukemiaTolerability and outcome of once weekly liposomal amphotericin B for the prevention of invasive fungal infections in hematopoietic stem cell transplant patients with graft-versus-host disease.Adjuvant therapy for resected non-small-cell lung cancer: recent advances, emerging agents, and lingering questions.A rare fraction of drug-resistant follicular lymphoma cancer stem cells interacts with follicular dendritic cells to maintain tumourigenic potentialOutcomes for newly diagnosed patients with acute myeloid leukemia dosed on actual or adjusted body weight.Acute myeloid leukemia: focus on novel therapeutic strategies.Evaluation of cytomegalovirus reactivation and tolerability in seropositive umbilical cord transplant patients after implementation of an intensive prevention strategy.Erythropoietin modulation is associated with improved homing and engraftment after umbilical cord blood transplantation.Evaluation of Performance Status and Hematopoietic Cell Transplantation Specific Comorbidity Index on Unplanned Admission Rates in Patients with Multiple Myeloma Undergoing Outpatient Autologous Stem Cell Transplantation.Utility of routine surveillance imaging for diffuse large B-cell lymphoma post autologous transplant: A single center experience.Utility of Routine Surveillance Imaging for Hodgkin Disease following Autologous Transplant: Experiences from a Single Institution.A novel hematopoietic progenitor cell mobilization regimen, utilizing bortezomib and filgrastim, for patients undergoing autologous transplant.Effect of extracorporeal photopheresis on lung function decline for severe bronchiolitis obliterans syndrome following allogeneic stem cell transplantation.Long-term results of a pilot study evaluating hyperbaric oxygen therapy to improve umbilical cord blood engraftmentA phase 2 study to assess the pharmacokinetics and pharmacodynamics of CPX-351 and its effects on cardiac repolarization in patients with acute leukemias.Cancer stem cells: the root of the problemUmbilical cord graft-versus-leukemia effect induces remission without the price of graft-versus-host disease: the possible role of NK cellsRituximab as a treatment for factor VIII inhibitor in a patient with chronic GVHDRetrospective evaluation of fidaxomicin versus oral vancomycin for treatment of Clostridium difficile infections in allogeneic stem cell transplantFatal GvHD induced by PD-1 inhibitor pembrolizumab in a patient with Hodgkin's lymphomaCPX-351 (cytarabine and daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary Acute Myeloid LeukemiaEpstein-Barr viremia and post-transplant lymphoproliferative disorders in patients undergoing haploidentical stem cell transplantation with post-transplant cyclophosphamideA novel extracellular matrix-based leukemia model supports leukemia cells with stem cell-like characteristicsSafety and efficacy of vismodegib in relapsed/refractory acute myeloid leukaemia: results of a phase Ib trialOvercoming Wnt-β-catenin dependent anticancer therapy resistance in leukaemia stem cellsA Phase 1B Clinical Study of Combretastatin A1 Diphosphate (OXi4503) and Cytarabine (ARA-C) in Combination (OXA) for Patients with Relapsed or Refractory Acute Myeloid LeukemiaVenetoclax Combined With Low-Dose Cytarabine for Previously Untreated Patients With Acute Myeloid Leukemia: Results From a Phase Ib/II StudyResults of the First Clinical Study in Humans That Combines Hyperbaric Oxygen Pretreatment with Autologous Peripheral Blood Stem Cell Transplantation
P50
Q28743931-4E2584AC-A28D-49BF-B52B-172DF896E416Q33821459-EC7C5E69-DA4B-49B6-957C-583CFF7E2D44Q33944909-33FDA88A-EA65-4EC7-A5A6-AF667EECFB2DQ33959401-80451DB2-000C-4F24-9B95-2C9F03DA90F5Q33992120-5128AB79-6D25-4990-81A4-1B4BADE2439FQ34522735-43DFE380-44E5-4D26-BA6E-7582773C8D86Q34785645-8ADA2163-7AAB-4AE1-BB86-1C96F468D8B5Q35356620-5DE6F773-AC26-4A56-9EC9-E529D53C243DQ35469344-2E3FD2AD-E1BA-47C5-8960-C221DA972C30Q35680443-69ECA4B4-3231-4E4B-B361-4FFA2720D86DQ35783036-F3ABC6D4-B825-4ADB-9B66-CE7017EBE400Q36028412-0AB8329F-C53A-4063-9479-BB01C3743321Q36498580-137A5D02-A952-404A-BA08-624A6CBD4FCFQ38015336-A857E740-7038-49CF-8D6B-C2E16589B176Q38788199-B8C3D30E-0F85-4F04-BC6C-D96959B242B3Q46810847-F8C8C808-202C-4076-8266-03DC4ECAF584Q48505132-1BCB1376-8322-49C5-ACF2-7D545BF1F008Q49572361-31F52815-09C0-4B0C-96D6-BBFC1F2C529EQ50019558-83268DE6-C44D-44D1-993B-A73C00CD0349Q50699759-84E21088-2123-474E-9243-8286E1DB60B3Q51626350-D08AB3F4-B2E3-42EE-9ED7-19B0D60ADB0BQ58086353-CAF82598-9BD2-49D5-A1F8-6D2BB5117938Q64967606-DC45F60F-7DE6-4F60-A3B6-57C24C9B1D18Q80826175-F19F2796-3B36-4055-95DE-9717DFFEB905Q84909789-25829750-8712-4C29-85F7-94136AE84805Q87126924-DEFCAEE3-06CB-4B0F-BBB3-DA48F7F2D89FQ89178901-6A0582A5-9C3D-4E2E-963C-6322F3F0FE7DQ89291887-1155E620-ED1D-4C7E-8C88-CE694B18DDB4Q90340566-E6618E37-0DAF-4AF5-8484-687AE6A1CD34Q90449867-79162EC1-78E5-4EF2-B227-6B3623D8BDD6Q91064565-35362304-294A-42FF-AB4F-D2D0A903F6F5Q91377444-5C3D3A6E-60AA-49E6-B42C-0980383B461EQ92094127-454FCF7B-7DC6-4991-AE2C-853CCF1A3011Q92326780-59DC3B46-2590-4C94-AC55-789F7315BFD7Q92502579-D84EE1A4-9FDF-461A-B42E-67BCD1E5F17EQ92564565-71430AC9-8CA3-4252-8A23-41BED52CE32B
P50
description
investigador
@es
researcher
@en
wetenschapper
@nl
name
Tara L Lin
@en
Tara L Lin
@nl
type
label
Tara L Lin
@en
Tara L Lin
@nl
prefLabel
Tara L Lin
@en
Tara L Lin
@nl
P31
P496
0000-0002-0242-6449